23 October 2015
EMA/CHMP/696163/2015
Procedure Management and Committees Support Division

Committee for medicinal products for human use (CHMP)

Minutes of the meeting on 21-24 September 2015

Chair: Tomas Salmonson – Vice-Chair: Pierre Demolis

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 21-24 September 2015.

1.2. Adoption of agenda

CHMP agenda for 21-24 September 2015.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 20-23 July 2015.

The CHMP adopted the minutes.

1.4. Membership Announcement

The Committee noted that Sinan B. Sarac was nominated as new Danish CHMP alternate, replacing Christian Schneider, Patrícia Silva was nominated as new Portuguese CHMP alternate, replacing Dinah Duarte and Bjorg Bolstad was nominated as new Norwegian alternate, replacing Ingunn Hagen Westgaard.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. Nucala - mepolizumab - EMEA/H/C/003860

GlaxoSmithKline Trading Services; treatment of asthma

Scope: Oral Explanation**Action:** An Oral Explanation to be held on Tuesday 22 September 2015 at 11:00, was cancelled.

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.03.2015.

See also 3.1.10.

2.1.2. - recombinant l-asparaginase - Orphan - EMEA/H/C/002661

medac Gesellschaft fuer klinische Spezialpraeparate mbH; combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL)

Scope: Oral explanation

Action: An Oral explanation was held on Wednesday 23 September 2015 at 11.00.

List of Outstanding Issues adopted on 21.05.2015. List of Questions adopted on 25.04.2014.

Company's presentation focused on the plans for production and distribution of the product in EU and to the efficacy and safety aspects.

See 3.2.18

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Tecfidera - Dimethyl Fumarate - EMEA/H/C/002601/WS0689/G; NAPs included in WS: Fumaderm, Fumaderm Intial

Biogen Idec Ltd,

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: Oral explanation and Opinion

Action: An Oral explanation was held on Tuesday 22 September 2015 at 14.00

Update of sections 4.4 of the SmPC in order to add a recommendation to consider interruption of treatment in patients with low lymphocyte counts (<0.5 x 109/L) persisting for more than six months and to monitor lymphocyte counts until recovery. Update of section 4.8 of the SmPC with information on observed low lymphocyte counts in clinical studies with Tecfidera and PML (Progressive multifocal leukoencephalopathy) occurrence in the setting of severe and prolonged lymphopenia. Furthermore, the due dates of two commitments as part of the RMP have been revised."

Request for Supplementary information adopted on 26.02.2015, 23.04.2015, 23.07.2015. SAG Neurology held on 11 June 2015.

Participation of patients' representatives

See also 9.1.5

2.3.2. TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0057

Takeda Austria GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Oral explanation and Opinion

"Extension of indication for the use of Tachosil as suture line sealing in dura mater closure. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC and the Package leaflet are updated. The MAH also took the opportunity to make minor editorial corrections to the product information."

Action: An Oral explanation was held on Tuesday 22 September 2015 at 17.00.

Request for Supplementary Information adopted on 21.05.2015, 22.01.2015.

See 5.1.13

2.4. Referral procedure oral explanations

2.4.1. Iogol and associated names soft capsules, 25 / 50 mg - diclofenac epolamine - EMEA/H/A-29/1414

Regiomedica GmbH

Rapporteur: Martina Weise, Co-Rapporteur: Concepcion Prieto Yerro,

Scope: Oral explanation and Opinion

Disagreements regarding the demonstration of bioequivalence with the reference product

See also 10.4.1.

Action: An Oral explanation was held on Tuesday 22 September 2015 at 09.00.

RMS: DE, CMS: AT, BE, CZ, EL, ES, HU, IT, PL, SK, UK, Decentralised procedure number: DE/H/3633/002-003/DC

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Aripiprazole Accord - aripiprazole - EMEA/H/C/004021

Accord Healthcare Ltd; treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Abilify

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 18.12.2014.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.2. Blincyto - blinatumomab - Orphan - EMEA/H/C/003731

Amgen Europe B.V.; treatment of Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.02.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that blinatumomab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 23.09.2015.

The summary of opinion was circulated for information.

The Committee adopted the BWP report.

3.1.3. Ciambra - pemetrexed - EMEA/H/C/003788

Menarini International Operations Luxembourg S.A.; Treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Alimta

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.02.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.4. Cotellic - cobimetinib - EMEA/H/C/003960

Roche Registration Ltd; treatment of metastatic melanoma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 22.01.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that cobimetinib is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.5. Elocta - efmoroctocog alfa - Orphan - EMEA/H/C/003964

Biogen Idec Ltd; Treatment of Haemophilia A

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.02.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that efmoroctocog alfa is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The Committee adopted the BWP report.

3.1.6. Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042

Gilead Sciences International Ltd; Treatment of HIV-1

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 23.04.2015.

The CHMP discussed the level of detail given in different sections of the SmPC. The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tenofovir alafenamide is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.7. Ionsys - fentanyl - EMEA/H/C/002715

Incline Therapeutics Europe Ltd; treatment of acute moderate to severe post-operative pain

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 22.01.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to special and restricted medical prescription.

The CHMP noted the letter of recommendation dated 22.09.2015.

The summary of opinion was circulated for information.

3.1.8. Kyprolis - carfilzomib - Orphan - EMEA/H/C/003790

Amgen Europe B.V.; treatment of multiple myeloma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 25.06.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that carfilzomib is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.9. Numient - levodopa / carbidopa - EMEA/H/C/002611

Impax Laboratories Netherlands BV; symptomatic treatment of adult patients with Parkinson's disease

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.03.2015.

The Committee confirmed that all issues previously identified in this application had been addressed. The CHMP discussed the need for an ERA study as the environmental exposure might be increased due to significantly lower bioavailability.

However, the Committee concluded that no ERA study is needed.The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The CHMP adopted the Assessment Report on similarity

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.10. Nucala - mepolizumab - EMEA/H/C/003860

GlaxoSmithKline Trading Services; treatment of asthma

Scope: Oral explanation or Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.03.2015.

Oral Explanation was cancelled – see 2.1.1.

The CHMP discussed the wording of the indication especially whether a cut-off for blood eosinophilia should be included and agreed not to include a specific cut off in the indication. The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that mepolizumab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The Committee adopted the BWP report.

3.1.11. Orkambi - lumacaftor / ivacaftor - Orphan - EMEA/H/C/003954

Vertex Pharmaceuticals (Europe) Ltd.; treatment of cystic fibrosis

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.03.2015.

The members discussed the duration of follow up in the long-term study and expressed their view in favour for a longer follow-up. The CHMP noted that the applicant accepted the longer follow up period which had been recommended by CHMP. The Committee confirmed that all issues previously identified in this application have been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that Lumacaftor is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 23.09.2015.

The summary of opinion was circulated for information.

3.1.12. Pemetrexed Hospira - pemetrexed - EMEA/H/C/003970

HOSPIRA UK LIMITED; treatment of malignant pleural mesothelioma and non-small cell lung cancer (excluding predominantly squamous cell histology)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Alimta

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.02.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The CHMP noted the letter of recommendation dated 23.09.2015.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.13. Pemetrexed medac - pemetrexed - EMEA/H/C/003905

medac Gesellschaft fur klinische Spezialpraparate mbH; Treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Alimta

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.02.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.14. Praxbind - idarucizumab - EMEA/H/C/003986

Boehringer Ingelheim International GmbH; Prevention and treatment of dabigatran associated haemorrhage

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 23.07.2015. Accelerated assessment.

The CHMP discussed the final wording of the indication and recommendations to the prescribers. The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that idarucizumab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The Committee adopted the BWP report.

3.1.15. Ravicti - glycerol phenylbutyrate - Orphan - EMEA/H/C/003822

Horizon Therapeutics Limited; treatment of patients with urea cycle disorders

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 23.10.2014.

The CHMP discussed the CE mark of the syringe as well as the indication wording.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation

timetable.

Furthermore, the CHMP considered that glycerol phenylbutyrate is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

Post-meeting note: Revision to the opinion had been done in accordance with discussions at CHMP.

The final documents were adopted via written procedure on 06.10.2015.

3.1.16. Ebymect - dapagliflozin / metformin - EMEA/H/C/004162

AstraZeneca AB; diabetes mellitus type 2

Scope: Opinion

Action: For adoption

Informed consent application (Article 10c of Directive No 2001/83/EC)

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.17. Edistride - dapagliflozin - EMEA/H/C/004161

AstraZeneca AB; Diabetes mellitus, type 2

Scope: Opinion

Action: For adoption

Informed consent application (Article 10c of Directive No 2001/83/EC)

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.18. Cinacalcet Mylan - cinacalcet - EMEA/H/C/004014

MYLAN S.A.S.; treatment of secondary hyperparathyroidism and hypercalcaemia

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Mimpara

List of Questions adopted on 21.05.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.19. Kolbam – Cholic Acid - Orphan - EMEA/H/C/002081

Retrophin Europe Ltd, treatment of inborn errors of primary bile acid synthesis

Rapporteur: Robert James Hemmings, Co-Rapporteur: Patrick Salmon, Scope: Revised opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

The Committee adopted a revised opinion recommending the granting of a marketing authorisation under exceptional circumstances by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

3.1.20. Entresto - sacubitril / valsartan - EMEA/H/C/004062

Novartis Europharm Ltd; treatment of heart failure (NYHA class II-IV)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

The Committee discussed the wording of the indication and whether the medicine should be used as first or second line. The Committee considered the first line treatment appropriate.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by majority (29 positive out of 30 votes) together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that sacubitril is a new active substance, as claimed by the applicant.

The divergent position (Daniela Melchiorri) was appended to the opinion.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The CHMP noted the letter of recommendation dated 24.09.2015.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.2. Initial applications; Day 180 list of outstanding issues

3.2.1. - brivaracetam - EMEA/H/C/003898

treatment of partial-onset seizures

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. - mercaptamine - Orphan - EMEA/H/C/004038

Lucane Pharma; treatment of corneal cystine deposits

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 26.03.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. - eptifibatide - EMEA/H/C/004104

prevention of early myocardial infarction

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. - ferric maltol - EMEA/H/C/002733

treatment of iron deficiency anaemia

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. - octocog alfa - EMEA/H/C/004147

treatment and prophylaxis of haemophilia A
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), Treatment and prophylaxis of haemophilia A
Treatment and prophylaxis of haemophilia A

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee adopted the BWP report.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop with a specific timetable.

The Committee adopted the BWP report.

3.2.6. - octocog alfa - EMEA/H/C/003825

Treatment and prophylaxis of haemophilia A
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), Treatment and prophylaxis of haemophilia A
Treatment and prophylaxis of haemophilia A, treatment and prophylaxis of haemophilia A
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues .

The CHMP agreed to the request by the applicant for an extension to the clock stop with a specific timetable.

The Committee adopted the BWP report.

3.2.7. - dexamethasone acetate - Orphan - EMEA/H/C/004071

LABORATOIRES CTRS; treatment of symptomatic multiple myeloma in combination with other medicinal products

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 18.12.2014.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. - parathyroid hormone - Orphan - EMEA/H/C/003861

NPS Pharma Holdings Limited; treatment of hypoparathyroidism

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 26.03.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues . The Committee agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues with a specific timetable.

The CHMP agreed on the need for ad hoc expert meeting.

The Committee adopted a list of questions to the SAG .

Call for nomination of additional experts
The Committee adopted the BWP report.

3.2.9. - betulae cortex dry extract (5-10 : 1); extraction solvent: n-heptane 95% (w/w) - EMEA/H/C/003938

treatment of partial thickness wounds

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 26.02.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. - opicapone - EMEA/H/C/002790

Parkinson's disease and motor fluctuations

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. - pemetrexed - EMEA/H/C/004072

unresectable malignant pleural mesothelioma
metastatic non-small cell lung cancer

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 26.03.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.12. - pemetrexed - EMEA/H/C/004109

Treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 25.06.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. - necitumumab - EMEA/H/C/003886

treatment of squamous non-small cell lung cancer

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee adopted the BWP report.

The Committee was reminded of the status of this application and its remaining outstanding issues,
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.14. - etanercept - EMEA/H/C/004007

treatment of arthritis

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

The Committee adopted the BWP report.

3.2.15. - selexipag - Orphan - EMEA/H/C/003774

Actelion Registration Ltd.; treatment of pulmonary arterial hypertension (PAH; WHO Group I)

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues. The CHMP agreed to an extension to the clock stop to respond to the list of outstanding issues with a specific timetable.

3.2.16. - human fibrinogen / human thrombin - EMEA/H/C/003914

supportive treatment for improvement of haemostasis and as a suture support in vascular surgery

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 26.02.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

The Committee adopted the BWP report.

Postmeeting note: In a letter dated 29 September 2015 the applicant informed of the decision to withdraw the MAA for this product.

3.2.17. - talimogene laherparepvec - ATMP - EMEA/H/C/002771

treatment of adults with melanoma that is regionally or distantly metastatic

Scope: 2nd Day 180 list of outstanding issue

Action: For adoption

List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 22.01.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee agreed to the list of outstanding issues as adopted by the CAT and added an additional question. The Committee adopted the specific timetable.

The Committee adopted the BWP report.

3.2.18. - recombinant l-asparaginase - Orphan - EMEA/H/C/002661

medac Gesellschaft fuer klinische Spezialpraeparate mbH; combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL)

Scope: Oral explanation

Action: An Oral explanation was held on Wednesday 23 September 2015 at 11.00.

List of Outstanding Issues adopted on 21.05.2015. List of Questions adopted on 25.04.2014.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The Committee adopted the BWP report.

3.3. Initial applications; Day 120 list of questions

3.3.1. - docetaxel - EMEA/H/C/004086

treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. - eluxadoline - EMEA/H/C/004098

for the treatment of irritable bowel syndrome with diarrhoea

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094

treatment of HIV

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. - lutetium (177 lu) chloride - EMEA/H/C/003999

radiolabelling of carrier molecules, which have been specifically developed for radiolabelling with this radionuclide

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. - dinutuximab beta - Orphan - EMEA/H/C/003918

APEIRON Biologics AG; treatment of neuroblastoma

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The Committee adopted the BWP report.

3.3.6. - chlormethine - Orphan - EMEA/H/C/002826

Actelion Registration Ltd.; treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL)

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. - irinotecan - Orphan - EMEA/H/C/004125

Baxter Innovations GmbH; treatment of pancreatic cancer

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. - palonosetron - EMEA/H/C/004129

prevention of nausea and vomiting associated with cancer chemotherapy

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. - palonosetron - EMEA/H/C/004069

prevention of nausea and vomiting associated with cancer chemotherapy

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. - saxagliptin / dapagliflozin - EMEA/H/C/004057

treatment of type 2 diabetes

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. - autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence - Orphan - ATMP - EMEA/H/C/003854

GlaxoSmithKline Trading Services; severe combined immunodeficiency

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application. The CHMP was updated on the discussions at the CAT and the list of questions adopted at the September CAT meeting.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions adopted by the CAT.

The Committee adopted the BWP report.

3.3.12. - ixekizumab - EMEA/H/C/003943

treatment of moderate to severe plaque psoriasis

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The Committee adopted the BWP report.

3.3.13. - ceftazidime / avibactam - EMEA/H/C/004027

treatment of cIAI, cUTI, nosocomial pneumonia

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application. .
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. - amikacin - Orphan - EMEA/H/C/003936

Insmed Limited; treatment of Pseudomonas aeruginosa lung infection/colonisation in cystic fibrosis patients, treatment of nontuberculous mycobacterial lung infection

Scope: Similarity assessment

Action: For adoption

The CHMP noted the letter from the applicant dated 21 August 2015 informing that the Sponsor will offer no additional data on the Similarity Assessment and decided to withdraw the indication for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.

3.4.2. - glycopyrronium bromide - EMEA/H/C/003883

treatment of sialorrhoea

Scope: Letter from the applicant dated 7 August 2015 requesting an extension of clock stop to submit the responses to the Day 120 list of questions.

Action: For adoption

List of Questions adopted on 25.06.2015.

The CHMP agreed to the request by the applicant for an extension of clock stop to submit the responses to the Day 120 list of questions with a specific timetable.

3.4.3. - drisapersen - Orphan - EMEA/H/C/003846

BioMarin International Limited; treatment of Duchenne muscular dystrophy (DMD)

Scope: Similarity assessment

Action: For adoption

The CHMP adopted the Assessment Report on similarity

3.4.4. - sirolimus - Orphan - EMEA/H/C/003978

Santen Oy; treatment of chronic non-infectious uveitis of the posterior segment of the eye

Scope: Letter from the applicant dated 8 September 2015 requesting an extension of clock stop to respond to Day 120 list of questions adopted on 25.06.2015.

Action: For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to Day 120 list of questions adopted on 25.06.2015.

3.4.5. - miglustat - EMEA/H/C/004016

treatment of Gaucher disease

Scope: Letter from the applicant dated September 2015 requesting an extension of clock stop to respond to Day 120 list of questions adopted on 23.07.2015.

Action: For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to Day 120 list of questions with a specific timetable.

3.4.6. - mercaptamine - Orphan - EMEA/H/C/003769

Orphan Europe S.A.R.L.; treatment of cystinosis

Scope: Letter from the applicant dated 15 September 2015 requesting to postpone the planned oral explanation to CHMP plenary to be held on 19-22 October 2015.

Action: For information

List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 22.01.2015.

The CHMP agreed to the request by the applicant to postpone the Oral Explanation to October 2015.

3.4.7. - ixazomib - Orphan - EMEA/H/C/003844

Takeda Pharma A/S; multiple myeloma

Scope: Timetable for assessment of similarity

Action: For adoption

The CHMP adopted the timetable for assessment of similarity

3.4.8. - pancreas powder - EMEA/H/C/002070

treatment in exocrine pancreatic insufficiency

Scope: Letter from the applicant dated 10 July 2015 requesting an extension of clock stop to respond to Day 120 list of questions adopted on 25.06.2015.

Action: For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to Day 120 list of questions adopted on 25.06.2015.

3.4.9. - methotrexate - EMEA/H/C/003756

treatment of rheumatological and dermatological diseases

Scope: Letter from the applicant requesting an extension of clock stop to respond to Day 120 list of questions adopted on 23 July 2015.

Action: For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to Day 120 list of questions adopted on 23 July 2015 with a specific timetable.

3.4.10. - enoxaparin sodium - EMEA/H/C/003795

prophylaxis of thromboembolic disorders of venous origin

Scope: Letter from the applicant requesting an extension of clock stop to respond to Day 120 list of questions adopted on 23 July 2015.

Action: For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to Day 120 list of questions adopted on 23 July 2015 with a specific timetable.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Heparesc - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)

Scope: Provisional timetable, List of experts to expert meeting

Action: For information

The CHMP agreed to the List of Questions as adopted by the CAT with a specific timetable.

Furthermore they agreed to consult an ad-hoc expert group and agreed to the List of Questions to the experts as adopted by the CAT.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/X/0034/G

Vertex Pharmaceuticals (Europe) Ltd.

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia

Scope: "Line extension to the Marketing Authorisation to include a new pharmaceutical form (granules) in two new strengths (50 mg and 75 mg unit doses) to enable administration of Kalydeco to patients aged 2 to less than 6 years of age. Changes to SmPC sections 4.2, 4.4, 4.5, 4.8 and 5.2 to provide clarity and relevant updates in line with the proposed paediatric extension application. Consequential changes are made to the Package Leaflet and Annex II of the MA."

Action: For adoption

List of Outstanding Issues adopted on 23.07.2015, 21.05.2015. List of Questions adopted on 26.02.2015.

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP adopted the Assessment Report on similarity

The CHMP agreed by consensus to the request for an additional 1 year of market protection.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

4.1.2. Suboxone - buprenorphine / naloxone - EMEA/H/C/000697/X/0029

RB Pharmaceuticals Ltd.

Rapporteur: Martina Weise

Scope: "Line extension application to add 12mg/3mg and 16mg/4mg sublingual tablets."

Letter from the MAH dated September 2015 informing of the decision to withdraw the application 12mg/3 mg strength sublingual tablets.

Action: For adoption

List of Outstanding Issues adopted on 21.05.2015. List of Questions adopted on 22.01.2015.

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

4.1.3. Iclusig - ponatinib - Orphan - EMEA/H/C/002695/X/0023

ARIAD Pharma Ltd

Rapporteur: Rafe Suvarna,

Scope: "Addition of a new strength of 30 mg film-coated tablets to the approved strengths of 15 mg and 45 mg film-coated tablets.

Editorial changes have been introduced to the quality information of the existing strengths."

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.2.1. Lojuxta - lomitapide - EMEA/H/C/002578/X/0016

Aegerion Pharmaceuticals Limited

Rapporteur: Pieter de Graeff,

Scope: "The applicant has submitted an application for a line extension to include 30 mg, 40 mg and 60 mg hard capsules."

Action: For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP adopted a list of outstanding issues with a specific timetable.

4.2.2. Emend - aprepitant - EMEA/H/C/000527/X/0049/G

Merck Sharp & Dohme Limited

Rapporteur: Filip Josephson, Co-Rapporteur: Pieter de Graeff, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "The MAH has submitted a type II variation classified as C.I.6 to extend the indication for chemotherapy-induced nausea and vomiting (CINV) in adults to paediatric patients (12 to 17years) for the 80mg and 125mg hard capsules. SmPC section 4.2 and 5.3 of the 165mg hard capsule label, which is consequential to the outcome of this grouped procedure, will be updated under the scope of type II variation classified as C.I.6.
In addition to this, an application for an addition of a new pharmaceutical form (powder for oral suspension) has been submitted for 125mg strength as part of this grouping.
The MAH has also submitted a type II variation classified as C.I.4 to reflect the paediatric results for prevention of post-operative nausea and vomiting (PONV) in the clinical sections of 40mg hard capsules label, thus updating sections 5.1 and 5.2 of the SmPC.
The Package Leaflet has been proposed to be updated accordingly."

Action: For adoption

List of Questions adopted on 23.04.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues. The main discussion focused on the wording of the indication as well on Adverse Drug Reporting frequencies for the SmPC.

The CHMP adopted a list of outstanding issues with a specific timetable.

4.2.3. Pyramax - pyronaridine / pyronaridine phosphate / artesunate - EMEA/H/W/002319/X/0008/G

Shin Poong Pharmaceutical Co., Ltd.

Rapporteur: Joseph Emmerich, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Isabelle Robine

Scope: "Line Extension to add a new paediatric formulation PYRAMAX 60 mg/20 mg Granules for Oral Suspension.
The PI for Pyramax 180 mg/60 mg Film Coated Tablets has also been updated with data submitted for the line extension."

Action: For adoption

List of Questions adopted on 26.02.2015.

The Committee was reminded of the status of this application and its remaining outstanding issues. The discussions focused on the phase IV study protocol, some quality aspects as well as the SmPC wording.

The CHMP adopted a 2nd list of outstanding issues with a specific timetable.

4.3. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.3.1. Reyataz - atazanavir / atazanavir sulfate - EMEA/H/C/000494/X/0094/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Joseph Emmerich, Co-Rapporteur: Rafe Suvarna, PRAC Rapporteur: Isabelle Robine

Scope: "An extension application covering a new pharmaceutical form (oral powder), a new strength for the oral powder presentation (50mg), and a new paediatric indication (patients from 3 months of age and weighing at least 5kg); a type II variation (C.1.6) to updated Reyataz capsules in light of new paediatric data; a type IB (C.I.11) variation to make minor revisions to the RMP with regards to nephrolithiasis, following PRAC's assessment of RMP version 7.3."

Letter from the applicant dated 18 September 2015 requesting an extension of clock stop to respond to the Request for Supplementary Information adopted in July 2015.

Action: For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the List of Outstanding Issues adopted in July 2015, with a specific timetable.

4.3.2. Instanyl - fentanyl / fentanyl citrate - EMEA/H/C/000959/X/0030/G

Takeda Pharma A/S

Rapporteur: Pierre Demolis, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Isabelle Robine

Scope: Annex I_2.(c) To add the new strength of 400 micrograms/dose in a multi-dose nasal spray in pack size of 10's, 20's, 30's & 40 doses. Type II cat. B.II.e.4.b) To replace the current multi-dose nasal spray by a new improved child resistant multi-dose nasal spray. 3 X Type IB cat. B.II.e.5.d) To add a new packsize of 30 doses for each current strength (50 micrograms/dose, 100 micrograms/dose & 200 micrograms/dose). Type IA cat. B.II.d.1.a) – To tighten the assay release limit of the multi-dose finished product to 98.0%-102.0%. Type IA cat. B.II.f.1.a) 1. – To reduce the shelf life of all strengths of the multi-dose finished product to 24 months. Additionally, the Applicant took the opportunity to include an editorial change, as to change the wording of the specification footnote regarding the droplet size distribution test from "The test is performed by the vendor on every pumping system batch" to "The test is performed at release of the pumping system".

Letter from the applicant dated 9 September 2015 requesting an extension of clock stop to respond to the List of Outstanding Issues adopted in July 2015.

Action: For information

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 26.02.2015.

4.4. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Abilify - aripiprazole - EMEA/H/C/000471/II/0110

Otsuka Pharmaceutical Europe Ltd

Rapporteur: Bruno Sepodes,

Scope: "Extension of Indication to include treatment of schizophrenia in adolescents between 13 – 15 years of age based on paediatric studies 31-09-266 and 31-09-267 submitted according to Article 46 of the paediatric regulation. As a consequence sections 4.1, 4.2 and 4.8 of the SmPC have been updated and the Package Leaflet has been updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application. The main issue related on clinical efficacy as further data from the conducted clinical trials was required for the assessment.

The Committee adopted 2nd Request for Supplementary Information with a specific timetable.

5.1.2. Cyramza - ramucirumab - Orphan - EMEA/H/C/002829/II/0003

Eli Lilly Nederland B.V.

Rapporteur: Pieter de Graeff, Co-Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to include new indication for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression after platinum-based chemotherapy for CYRAMZA.
As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, one minor typographical error was corrected in section 4.2 of the SmPC.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 21.05.2015.

The Committee discussed the issues identified in this application, which were related to the benefit/risk in patients older than 65 years of age and external validity of the ramucirumab data. The Committee concluded that the MAH should further justify ramucirumab as treatment option in NSCLC.

The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

5.1.3. Cyramza - ramucirumab - Orphan - EMEA/H/C/002829/II/0004

Eli Lilly Nederland B.V.

Rapporteur: Pieter de Graeff, Co-Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to include a new indication for Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, the Marketing authorisation holder (MAH) took the opportunity to correct minor editorial mistakes."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

The Committee discussed the issues identified in this application, which were related to the B/R, toxicity (neutropenia) and efficacy. The Committee was on a view that further information is needed on B/R, which could be enhanced by patient selection, in particular on the basis of biomarkers.

The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

5.1.4. Eylea - aflibercept - EMEA/H/C/002392/II/0021

Bayer Pharma AG

Rapporteur: Pierre Demolis, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Isabelle Robine

Scope: "Extension of Indication to include a new indication for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).
As a consequence, SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 are updated. The Package Leaflet is updated in accordance. In addition, some editorial changes are proposed in the SmPC, Annex II and the PL."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.5. Gilenya - fingolimod - EMEA/H/C/002202/II/0034

Novartis Europharm Ltd

Rapporteur: Pierre Demolis, Co-Rapporteur: Filip Josephson, Scope: Extension of indication: "Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy. As a consequence, section 4.1 of the SmPC is updated. In addition, the applicant took the opportunity to relocate documents from section 5.3.5.1 to 5.3.5.2."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2015.

The main discussion of the CHMP related to the wording of the indication. The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.6. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0027

Vertex Pharmaceuticals (Europe) Ltd.

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia

Scope: "Extension of indication for Kalydeco to include the treatment of cystic fibrosis in patients aged 18 years and older who have a R117H mutation in the CFTR gene. Consequently, changes are proposed to sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and to the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015, 26.02.2015, 23.10.2014.

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.7. Opdivo - nivolumab - EMEA/H/C/003985/II/0001

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults (in line with the Nivolumab BMS MAA, procedure EMEA/H/C/003840). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been revised accordingly. Further, Annex II has been updated to include a post-authorisation efficacy study as a new obligation in line with the agreed Annex II for Nivolumab BMS. In addition, the MAH took the opportunity to make editorial changes in the SmPC, Annex II, labelling and Package Leaflet. A revised RMP version 2.0 was provided as part of the application."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.8. Pyramax - pyronaridine / pyronaridine phosphate / artesunate - EMEA/H/W/002319/II/0002

Shin Poong Pharmaceutical Co., Ltd.

Rapporteur: Joseph Emmerich, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Isabelle Robine

Scope: "To amend SmPC section 4.1 (Therapeutic Indications) to remove restrictions on repeated course of treatment in any individual and use only in areas of low transmission with evidence of artesmisinin resistance, based on further clinical experience. Consequent changes in SmPC sections 4.2 (Posology), 4.4 (Special warnings and precautions), 4.8 (Undesirable effects) and the PL are also included.
A recommended change is made to SmPC Section 4.2 (Posology) in relation to dosing in mild to moderate renal impairment.
A minor editorial adjustment is proposed to SmPC section 5.1 (Pharmacodynamic properties)."

Action: For adoption

Request for Supplementary Information adopted on 23.04.2015, 18.12.2014, 26.06.2014.

The Committee discussed the issues identified in this application.

The Committee adopted a 4th Request for Supplementary Information with a specific timetable.

5.1.9. Rebetol - ribavirin - EMEA/H/C/000246/II/0074

Merck Sharp & Dohme Limited

Rapporteur: Joseph Emmerich

Scope: "Change of the indication of Rebetol to reflect that ribavirin is indicated in the treatment of hepatitis C in combination with other medicinal products and to remove reference to the peginterferon used (2a or 2b) in line with the PRAC recommendation in the PSUR assessment (EMEA/H/C/PSUSA/000100007/201307). As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.7, 4.8, 4.9 and 5.1 of the SmPC are updated. The variation proposed amendments to the Summary of Product Characteristics, Labelling, Annex II and Package Leaflet."

Action: For adoption
Request for supplementary information adopted on 25.06.2015, 26.03.2015, 23.10.2014.
The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.10. Vidaza - azacitidine - Orphan - EMEA/H/C/000978/II/0030

Celgene Europe Limited

Rapporteur: Pieter de Graeff, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Sabine Straus

Scope: "Extension of Indication to add treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification, based on the pivotal phase III study AZA- AML-001. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. A revised RMP version 10.0 was provided as part of the application. The application includes a request for an additional year of market protection for a new indication in accordance with Article 10(1) of Directive 2001/83/EC.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.04.2015.

The Committee confirmed that all issues previously identified in this application had been resolved.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.11. Volibris - ambrisentan - Orphan - EMEA/H/C/000839/II/0041

Glaxo Group Ltd

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Radka Montoniová, PRAC Rapporteur: Dolores Montero Corominas

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to include an expanded therapeutic indication for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1)
In addition, the MAH took the opportunity to update Annex II to reflect a change in the PSUR cycle.
The Package leaflet is proposed to be updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2015, 26.03.2015.

The Committee discussed the issues identified in this application, which related mainly to the wording of the indication.

The Committee adopted a 3rd Request for Supplementary Information with a specific timetable.

5.1.12. Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0022

AstraZeneca AB

Rapporteur: Greg Markey,

Scope: "Extension of Indication to include new population, children over the age of 2 months and adolescents, for Zinforo. As a consequence, sections 4.1, 4.2, 5.2, 5.3 and 6.6 of the SmPC are updated with new information on dosing, PK and pre-clinical safety. The Package Leaflet is updated in accordance. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a Request for Supplementary Information with a specific timetable.

5.1.13. TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0057

Takeda Austria GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Oral explanation and Opinion

"Extension of indication for the use of Tachosil as suture line sealing in dura mater closure. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC and the Package leaflet are updated. The MAH also took the opportunity to make minor editorial corrections to the product information."

Action: An Oral explanation was held on Tuesday 22 September 2015 at 17.00.

Request for Supplementary Information adopted on 21.05.2015, 22.01.2015.

The oral explanation focused on clinical efficacy data.

The Committee discussed the issues identified in this application.

The Committee adopted the 3rd Request for Supplementary Information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Nplate - romiplostim - Orphan - EMEA/H/C/000942/II/0051

Amgen Europe B.V.

Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Pieter de Graeff, PRAC Rapporteur: Dolores Montero Corominas

Scope: Letter from the MAH dated 4 August 2015 requesting extension of timeframe to respond to the Request for supplementary information adopted on 25 June 2015.

"Extension of Indication to include second line treatment of all non-splenectomised patients (including those without a contraindication to surgery). As a consequence, section 4.1 of the SmPC has been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives in Croatia and Italy in the Package Leaflet."

Action: For adoption

Request for supplementary information adopted on 25 June 2015.

The CHMP agreed to the request by the applicant for an extension of timeframe to respond to the Request for supplementary information adopted on 25 June 2015 with a specific timetable.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. – daratumumab - Orphan - H0004077

Janssen-Cilag International N.V., treatment of patients with multiple myeloma, who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double-refractory to a PI and IMiD

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company dated 30 July 2015 requesting an accelerated assessment.

The CHMP ***agreed*** to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

The CHMP noted the tentative accelerated timetable.

8.1.2. - Chlorhexidine – Article 58 - (H0003799)

for the prophylaxis of omphalitis (infection of the umbilical cord) in newborn infants

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company dated 30 June 2015 requesting an accelerated assessment.

The CHMP ***agreed*** to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Onglyza - Saxagliptin, Saxagliptin Hydrochloride - EMEA/H/C/001039/LEG 038

AstraZeneca AB, treatment of type 2 diabetes mellitus

Rapporteur: Pieter de Graeff, Co-Rapporteur: Karsten Bruins Slot,

Scope: Opinion

In 2014, the CHMP assessed a Type II variation (WS/0529/G) to reflect data outcomes from the SAVOR study in the product information. In April 2015, new FDA analyses relating to the SAVOR study were made available. Based on the new data and the assessment of the MAH's responses to a CHMP list of questions adopted in April 2015, the CHMP requested advice from the PRAC. Based on the review of the available information, the PRAC agreed that further clarification was needed regarding the underlying reasons for the observed imbalance in all-cause mortality before any conclusions on causality can be drawn. The PRAC agreed a list of questions to be addressed to the MAH. The PRAC will provide CHMP with further advice in September 2015 following the assessment of the MAH's responses to the list of questions.

Action: For adoption

See also 9.1.2

The CHMP agreed with the PRAC advice.

9.1.2. Komboglyze - Metformin Hydrochloride, Saxagliptin Hydrochloride - EMEA/H/C/002059/LEG 015

AstraZeneca AB, treatment of type 2 diabetes mellitus

Rapporteur: Pieter de Graeff, Co-Rapporteur: Karsten Bruins Slot,

Scope: Opinion

In 2014, the CHMP assessed a Type II variation (WS/0529/G) to reflect data outcomes from the SAVOR study in the product information. In April 2015, new FDA analyses relating to the SAVOR study were made available. Based on the new data and the assessment of the MAH's responses to a CHMP list of questions adopted in April 2015, the CHMP requested advice from the PRAC. Based on the review of the available information, the PRAC agreed that further clarification was needed regarding the underlying reasons for the observed imbalance in all-cause mortality before any conclusions on causality can be drawn. The PRAC agreed a list of questions to be addressed to the MAH. The PRAC will provide CHMP with further advice in September 2015 following the assessment of the MAH's responses to the list of questions.

Action: For adoption

See also 9.1.1

The CHMP agreed with the PRAC advice.

9.1.3. Aldurazyme – laronidase - EMEA/H/C/000477/S/0054

Genzyme Europe BV

Rapporteur: Greg Markey, PRAC Rapporteur: Rafe Suvarna

Scope: Annual reassessments for products with proposal for lifting exceptional circumstances

Action: For adoption

The Committee discussed the issues identified in this application. The Committee agreed in principle with the lifting of the exceptional circumstances to a standard marketing authorisation on the basis that further clarification regarding the registry continuation is provided.

The Committee adopted a Request for Supplementary Information with a specific timetable.

9.1.4. Cellcept - mycophenolate mofetil- EMEA/H/C/000082/II/0121

Roche Registration Ltd,

Rapporteur: Rafe Suvarna,

Scope: Request for Supplementary information
Update of sections 4.4 and 4.6 of the SmPC in order to add a warning for pregnant women and update the safety information related to pregnancy. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the PI in line with the latest QRD template version. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015, 26.03.2015.

The CHMP discussed the PRAC advice. According to PRAC advice, SmPC sections 4.3, 4.4 and 4.6 should be changed. The Committee discussed the DHPC communication, education materials for HCP and patients. Furthermore the advice on use during preganacy, need for informed consent before the start of treatment and need for EU Pregnancy registry was discussed.

The CHMP adopted a 3rd Request for Supplementary Information with a specific timetable.

9.1.5. Tecfidera - Dimethyl Fumarate - EMEA/H/C/002601/WS0689/G; NAPs included in WS: Fumaderm, Fumaderm Intial

Biogen Idec Ltd,

Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: Opinion

Update of sections 4.4 of the SmPC in order to add a recommendation to consider interruption of treatment in patients with low lymphocyte counts (<0.5 x 109/L) persisting for more than six months and to monitor lymphocyte counts until recovery. Update of section 4.8 of the SmPC with information on observed low lymphocyte counts in clinical studies with Tecfidera and PML (Progressive multifocal leukoencephalopathy) occurrence in the setting of severe and prolonged lymphopenia. Furthermore, the due dates of two commitments as part of the RMP have been revised."

Action: For adoption

Request for Supplementary information adopted on 26.02.2015, 23.04.2015, 23.07.2015. SAG Neurology held on 11 June 2015.

See also 2.3.1.

An oral explanation was held on Tuesday 22 September 2015 at 14.00. Participation of patients' representatives

The Company presented their proposal for patient monitoring in order to minimise the risk of PML. The possible therapeutic decision scenarios depending on ALC levels were presented.

Patients' representatives shared their opinion on intensified monitoring measures including more frequent MRIs (e.g. every 6 months), blood sampling (several times yearly), clinical examinations and also anti JCV antibody testing. The patients' representatives mentioned that the advantages of Tecfidera compared to current therapies – for example the fact that Tecfidera can be administered orally, should be taken into consideration in the discussion.

The Committee discussed the proposed therapeutic decision scenarios and the benefit of JCV antibody testing in Tecfidera treated patients. The Committee concluded that SmPC should state necessary details for monitoring of the therapy and made a proposal to the MAH.

The Committee adopted a Request for Supplementary Information with a specific timetable.

9.1.6. Xalkori - crizotinib (EMEA/H/C/002489) - EMEA/H/C/PSUSA/00010042/201502

Pfizer Limited,

Rapporteur: Pierre Demolis, PRAC Rapporteur: Corinne Fechant

Scope: Opinion

Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction “cardiac failure” with a frequency “common”. The Package leaflet is updated accordingly.

Action: For adoption

The CHMP agreed with the PRAC advice.

9.1.7. Votubia - everolimus – Orphan- EMEA/H/C/002311/II/0034

Novartis Europharm Ltd, treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS)

Rapporteur: Harald Enzmann,

Scope: Opinion

“Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update product information after completion of Long Term follow up on duration of responses and time to progression for study M2301 object of this submission. The Package Leaflet is updated accordingly. The data submitted are in fulfilment of SOB024 specific obligation for the conditional MA. With the fulfilment of SOB024 the MAH take the occasion to ask for the switch from conditional MA to full and to remove Votubia from the European list of additional monitored medicines.”

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report recommending the variation to the terms of the Marketing Authorisation. As all specific obligations laid down in Annex II have been fulfilled, pursuant to Article 7 of Regulation (EC) No 507/2006, the CHMP recommended by consensus the switching from a conditional to a full Marketing Authorisation.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.8. Zelboraf - vemurafenib - EMEA/H/C/002409/II/0024/G

Roche Registration Ltd,

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga,

Scope: Opinion

“Update of sections 4.4, 4.5 and 4.8 of the SmPC in order to update information on the risk of potentiation of radiation toxicity and updating the risk of progression of cancers with RAS mutations with information on progression of pre-existing pancreatic adenocarcinoma with

KRAS mutation. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2015.

The CHMP agreed to the wording of the DHPC and communication plan

9.1.9. Gilenya – fingolimod - EMEA/H/C/002202/R/0036

Novartis Europharm Ltd

Rapporteur: Pierre Demolis, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Isabelle Robine,

Scope: Renewals of Marketing Authorisations requiring 2nd Renewal

Action: For adoption

The CHMP adopted an opinion by consensus recommending that the risk-benefit balance of Gilenya remains favourable and therefore recommended by consensus the renewal of the Marketing Authorisation for the above mentioned medicinal product.

The CHMP was also of the opinion that one additional five-year renewal is required.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.10. Eviplera - emtricitabine / rilpivirine / tenofovir disoproxil - EMEA/H/C/002312/II/0063/G

Gilead Sciences International Ltd

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst,

Scope: Opinion or Request for Supplementary information

"Update of section 4.8 of the SmPC in order to add safety information regarding severe skin reactions with systemic symptoms. The Package Leaflet and the RMP (V10.0) are updated accordingly. The RMP has also been updated to update the RMP with results from previous procedure (EMEA/H/C/002312/II/0053), update the RMP in alignment with the RMP for the mono-component rilpivirine by deleting an important missing information safety concern (drug drug interactions) and update the RMP to amend the potential risk safety concern (off label use) to reflect use for the product and not the single component RPV. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the RMP for other minor issues."

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report recommending the variation to the terms of the Marketing Authorisation.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

10.1.1. Inductos - Dibotermin alfa – EMEA/H/A-20/1422/C/0408/0082

Medtronic BioPharma B.V., treatment of anterior lumbar spine fusion and tibia fracturesRapporteur: Pieter de Graeff, Co-Rapporteur: Outi Mäki-Ikola,

Scope: List of Outstanding Issues

Non-GMP compliance statement of a manufacturing site

Action: For adoption

The members were updated on the procedure.

The Committee adopted a list of outstanding issues with a specific timetable.

CHMP List of outstanding issues: 24.09.2015

Submission of responses: 02.10.2015

Re-start of the procedure: 05.10.2015

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 09.10.2015

Comments: 14.10.2015

Updated Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 16.10.2015

CHMP opinion: October 2015 CHMP

10.1.2. Tysabri - natalizumab – EMEA/H/A-20/1416/C/000603/0083

Biogen Idec Ltd, treatment of multiple sclerosis

Rapporteur: Jan Muller-Berghaus, Co-Rapporteur: Daniela Melchiorri,

Scope: List of Questions adopted by PRAC for the SAG neurology

Review of the benefit-risk balance following the notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004, based on pharmacovigilance data

Action: For adoption

The CHMP agreed to the list of questions adopted by the PRAC for the SAG Neurology.

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Iogol and associated names soft capsules, 25 / 50 mg - diclofenac epolamine - EMEA/H/A-29/1414

Regiomedica GmbH

Rapporteur: Martina Weise, Co-Rapporteur: Concepcion Prieto Yerro,

Scope: Oral Explanation and Opinion

Disagreements regarding the demonstration of bioequivalence with the reference product

Action: An oral explanation was held on 22 September 2015 at 09.00.

RMS: DE, CMS: AT, BE, CZ, EL, ES, HU, IT, PL, SK, UK, Decentralised procedure number: DE/H/3633/002-003/DC

See also 2.4.1

During the oral explanation, the applicant compared the pharmacokinetics of various EU approved immediate release diclofenac containing products. The applicant concluded that minor differences in Cmax and Tmax of Iogol capsules versus the reference product are not therapeutically relevant and that there are no efficacy concerns. Regarding the food effect, the applicant explained that intake with food increases Tmax and decreases Cmax, while having no significant effect on AUC. The applicant proposed the same administration instructions as for the reference product (diclofenac can be taken with or without food).

The Committee discussed the differences in Cmax and Tmax/AUC0-tmax between the test and the reference products. Some members were of the opinion that the differences were small and were not expected to affect the efficacy or safety of the test product. The members were of the opinion that diclofenac absorption is influenced by the presence of food in the stomach and gastric emptying rates, and that the food effect observed for the test product is an intrinsic property of the substance itself rather than due to the formulation. Some members favoured the same administration instructions as for the reference product.

However, other members were of the opinion that the differences in Cmax and AUCtmax between the test and the reference products seen in the bioequivalence study are relevant for NSAIDs, as both parameters affect the onset of action. Some members expressed their view that bioequivalence should have been investigated in the fed state.

The CHMP was informed by the applicant of the withdrawal of the DCP application for diclofenac epolamine 25 mg and 50 mg soft capsules, therefore no opinion was adopted.

10.4.2. Linxyd 2 mg/ml, solution for infusion and associated names – linezolid – EMEA/H/A-29/1423

Helm AG

Rapporteur: TBC, Co-Rapporteur: TBC,

Scope: Appointment of Rapporteurs, List of Questions and timetable

Disagreements regarding the suitability of the manufacturing process.

Action: For discussion

RMS: NL, CMS: IE, UK, Mutual Recognition procedure number: NL/H/3416/001/MR

The CHMP noted the letter from Medicines Evaluation Board in the Netherlands dated 30 July 2015 notifying of an official referral under article 29 and its grounds.

The CHMP appointed Johann Lodewijk Hillege as Rapporteur (interest level 1) and Greg Markey as Co-Rapporteur (interest level 1).

The CHMP adopted a list of questions with a specific timetable.

Notification: 15.09.2015

Start of procedure (CHMP): September 2015 CHMP

List of Questions: 24.09.2015

Submission of responses: 17.12.2015

Re-start of the procedure: 31.12.2015

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 13.01.2016

Comments: 18.01.2016

Updated rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 21.01.2016

List of outstanding issues or CHMP opinion: January 2016 CHMP

10.4.3. Linezolid Accord 2 mg/ml, solution for infusion and associated names – linezolid – EMEA/H/A-29/1424

Accord Healthcare Ltd

Rapporteur: TBC, Co-Rapporteur: TBC,

Scope: Appointment of Rapporteurs, List of Questions and timetable

Disagreements regarding the suitability of the manufacturing process.

Action: For discussion

RMS: NL, CMS: AT, BE, CY, DE, EE, ES, FI, FR, IE, IT, MT, PL, PT, UK, Mutual Recognition procedure number: NL/H/3365/001/MR

The CHMP noted the letter from the Medicines Evaluation Board in the Netherlands dated 30 July 2015 notifying of an official referral under article 29 and its grounds.

The CHMP appointed Johann Lodewijk Hillege as Rapporteur (interest level 1) and Greg Markey as Co-Rapporteur (interest level 1).

The CHMP adopted a list of questions with a specific timetable.

Notification: 15.09.2015

Start of procedure (CHMP): September 2015 CHMP

List of Questions: 24.09.2015

Submission of responses: 17.12.2015

Re-start of the procedure: 31.12.2015

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 13.01.2016

Comments: 18.01.2016

Updated rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 21.01.2016

List of outstanding issues or CHMP opinion: January 2016 CHMP

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

10.5.1. Durogesic transdermal patches – fentanyl - EMEA/H/A-30/1413

MAH: Janssen-Cilag group of companies and associated companies

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Martina Weise,

Scope: List of Questions and timetable

The CHMP noted the letter from the European Commission dated 15 September 2015 notifying of an official referral under Article 30.

Action: For adoption

The CHMP appointed Johann Lodewijk Hillege as Rapporteur (interest level 1) and Martina Weise as Co-Rapporteur (interest level 2).

The CHMP adopted a list of questions with a specific timetable.

Notification: 15.09.2015

Start of procedure (CHMP): September 2015 CHMP

List of Questions: 24.09.2015

Submission of responses: 23.10.2015

Re-start of the procedure: 19.11.2015

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 02.12.2015

Comments: 07.12.2015

Updated rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 10.12.2015

List of outstanding issues or CHMP opinion: December 2015 CHMP

10.5.2. Haldol and associated names (EMEA/H/A-30/1393) (haloperidol), Janssen-Cilag Group of companies and associated companies

Rapporteur: Martina Weise, Co-Rapporteur: Ana Dugonjić,

Scope: revised List of outstanding issues and questions to the HCPs

Action: For adoption

The Committee discussed the need to consult healthcare professionals organisations (HCPs) on the different indications and dose ranges covered by the set of questions identified in the official product information available in the Member States.

The CHMP adopted a revised list of outstanding issues and a list of questions to the HCPs with a specific timetable.

List of outstanding issues (LoOI): March 2015 CHMP

Responses to LoOI: 19.02.2016

Restart of the procedure: 04.03.20016

Assessment report: 15.03.2016

Comments from CHMP: 21.03.2016

List of outstanding issues 2 or CHMP opinion: April 2016 CHMP

10.5.3. Haldol decanoate and associated names (EMEA/H/A-30/1405) (haloperidol) Janssen-Cilag Group of companies and associated companies

Rapporteur: Martina Weise, Co-Rapporteur: Ana Dugonjić,

Scope: revised List of outstanding issues and questions to the HCPs

Action: For adoption

The Committee discussed the need to consult healthcare professionals organisations (HCPs) on the different indications and dose ranges covered by the set of questions identified in the official product information available in the Member States.

The CHMP adopted a revised list of outstanding issues and a list of questions to the HCPs with a specific timetable.

List of outstanding issues (LoOI): March 2015 CHMP

Responses to LoOI: 19.02.2016

Restart of the procedure: 04.03.20016

Assessment report: 15.03.2016

Comments from CHMP: 21.03.2016

List of outstanding issues 2 or CHMP opinion: April 2016 CHMP

10.5.4. Novantrone and associated names (EMEA/H/A-30/1399) (mitoxantrone)

MEDA group of companies and associated companies

Rapporteur: Pieter de Graeff, Co-Rapporteur: Robert Hemmings,

Scope: revised timetable

Harmonisation exercise for Novantrone and associated names. The review was triggered by the European Commission, due to the need of harmonisation of the Summary of Product Characteristics across Member States.

Action: For adoption

The CHMP was informed about the meeting date of the SAG Neurology for this procedure and adopted the updated timetable.

List of outstanding issues: July, 2015 CHMP

Submission of responses: 28.09.2015

Re-start of the procedure: 20.10.2015

Rapporteur joint assessment report circulated to CHMP: 04.11.2015

Scientific Advisory Group meeting: 06.11.2015

Comments from CHMP members: 09.11.2015

List of outstanding issues/CHMP opinion: November 2015 CHMP

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Gadolinium-containing contrast agents (GdCA): gadoversetamide – OPTIMARK (CAP) Gadobenate dimeglumine; gadobutrol; gadodiamide; gadopentetic acid dimeglumine, gadoteric acid (intra articular formulation); gadoteric acid (intrvenous and intravascular formulations); gadoteridol; gadoxetic acid disodium (NAP)

Lead Rapporteur: Rafe Suvarna,

Scope: Annual cumulative reviews on NSF cases submission as a post-authorisation measure resulting from the 2010 Article 20 and Article 31 referral procedures for gadolinium-containing contrast agents

Action: For adoption

The CHMP adopted the annual cumulative reviews.

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003

No items

10.10. Procedure under Article 29 Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

No items

11. Pharmacovigilance issue

11.1. Early Notification System

September 2015 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Summary of recommendations and advice of PRAC meeting held on 07-10 September 2015.

Action: For information

12. Inspections

12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information

13.2.1. ITF Briefing Meeting

Action: For adoption

The CHMP adopted the ITF briefing meeting

13.2.2. ITF Briefing Meeting

Action: For adoption

The CHMP adopted the ITF briefing meeting

13.2.3. ITF Briefing Meeting

Action: For adoption

The CHMP adopted the ITF briefing meeting

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Election of CHMP Chair

Action: For adoption

Dr Tomas Salmonson was elected as chair by the CHMP for a second 3-year mandate.

14.1.2. Discussion of CHMP co-opted member expertise

Action: For discussion

The CHMP discussed the area of expertise of the 5th CHMP co-opted member. Please send proposals . Further discussion on the area of expertise is planned at the October ORGAM and Plenary meeting.

14.1.3. Strategic Review & Learning Meeting under Luxembourg Presidency

Draft list of topics and agenda

Action: For discussion

The CHMP noted the draft agenda of the Strategic Review & Learning Meeting under Luxembourg Presidency, to take place 26 – 28.10.2015 in Luxembourg. Comments from the members should be sent.

14.1.4. Enhanced early dialogue to foster development and facilitate accelerated assessment

Scope: Concept Paper

Action: For discussion

The CHMP noted the update.

14.1.5. Follow-up discussion from Strategic Review & Learning Meeting in Rome on update of template for assessment of claims of additional year of marketing protection

Action: For adoption

Revised CHMP AR Template for assessment of claims of +1 year marketing protection.

The CHMP adopted the revised CHMP AR Template.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 07-10 September 2015

Action: For information

The members noted the Summary of recommendations and advices of the PRAC meeting.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for September 2015

Action: For adoption

The EURD list was adopted.

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 17-18 September 2015
Action: For information

The CHMP noted the draft Minutes.

14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 6-9 July 2015

Action: For information

The CHMP noted the report.

Letter from HMPC to CHMP (SWP) dated 15 September 2015 regarding the toxicological assessment of estragole in herbal medicinal products and on the potential impact on other medicinal products containing fennel, anise or other estragole-containing ingredients

Action: For discussion

The CHMP agreed to this request to the SWP.

14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at September 2015 PDCO

Action: For information

The CHMP noted the report.

Report from the PDCO meeting held on 9-11 September 2015

Action: For information

The CHMP noted the report.

14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 1-3 September 2015
Action: For information

The CHMP noted the report.

14.2.6. CMDh

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 21-23 September 2015

Action: For information

The CHMP noted the report.

Question from CMDh to CHMP/BWP on Biosimilars of Low Molecular Weight Heparins

Action: For adoption

The CHMP agreed to this request to the BWP.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 1-4 September 2015. Table of conclusions

Action: For information

Scientific advice letters: Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.2. Vaccines Working Party (VWP)

Nomination of Isabelle Bekeredjian-Ding (DE) as observer to Vaccines Working Party

Action: For adoption

The CHMP endorsed Isabelle Bekeredjian-Ding as observer to the VWP.

14.3.3. Cardiovascular Working Party

Guideline on clinical evaluation of medicinal products used in weight management

Overview of comments received

Action: For adoption

The CHMP adopted the Guideline.

Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients (EMA/CHMP/41252/2015)

Action: For adoption for 6-month public consultation

The CHMP postponed the adoption to October CHMP.

14.3.4. Pharmacokinetics Working Party

Responses to CMDh question to CHMP (PKWP, SWP) regarding potential risk of longer half-life of acitretin

Action: For adoption

CHMP asked PKWP and SWP to conduct further analysis on the available human PK data to try and establish a safety threshold in plasma. PKWP and SWP concluded that, in absence of a safe concentration threshold, it is not possible to stop contraceptive measures before the 3 year protection period (nor allow earlier blood donation) or recommend patient-specific longer protection periods based on acitretin or etretinate plasma concentration measurements. The CHMP adopted the responses to CMDh.

Response to CMDh question to CHMP (PKWP) regarding tacrolimus containing products – evaluation of bioequivalence

Action: For adoption

The CHMP adopted the responses to CMDh.

14.3.5. Invented name issues

Table of Decisions of September 2015 NRG written procedure

Action: For adoption

The CHMP adopted the Table of Decisions.

14.4. Cooperation within the EU regulatory network

14.4.1. Live broadcast of EFSA conference on food safety

The European Food Safety Authority (EFSA) is hosting a scientific conference on 14, 15 and 16 October entitled 'Shaping the future of food safety, together'. The conference will be attended by representatives from the scientific and risk-assessment community, as well as by risk managers from European and other countries. Interested colleagues can watch the conference via live broadcast from the website www.efsaexpo2015.eu and ask questions through a dedicated tool on that site, or via twitter using the hashtag #EFSAexpo2015.

Action: For information

The CHMP noted the information on the scientific conference.

14.5. Cooperation with International Regulators

14.5.1. Presentation on current status of EMA cooperation with FDA

The CHMP noted the update on current status of EMA cooperation with FDA. There will be new clusters on patient engagement and on paediatric development in rare diseases created. Furthermore, cooperation on pharmacovigilance inspections is explored.

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

14.6.1. International Society for Stem Cell Research

ISSCR's "Guidelines for Stem Cell Research and Clinical Translation" (EXT/601308/2015)

Action: For discussion

The CHMP noted the guidelines.

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Initial MAA submissions with appointed Rapporteurs 3 Q 2015

3Q 2015 planning update

Action: For information

The CHMP noted the planning update.

14.9. Others

No items

15. Any other business

15.1. AOB topic

16. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 21-24 September 2015 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Tomas Salmonson	Chair	Sweden	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Milena Stain	Alternate	Austria	No interests declared	
Daniel Brasseur	Member	Belgium	No interests declared	
Bart Van der Schueren	Alternate	Belgium	No interests declared	
Mila Vlaskovska	Member	Bulgaria	No interests declared	
Viola Macolić Šarinić	Member	Croatia	No interests declared	
Ana Dugonjić	Alternate	Croatia	No interests declared	
Panayiotis Triantafyllis	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czech Republic	No participation in discussions, final deliberations and voting on:	3.1.18 Cinacalcet Mylan - cinacalcet - EMEA/H/C/004014
Radka Montoniová	Alternate	Czech Republic	No interests declared	
Jens Heisterberg	Member	Denmark	No restrictions applicable to this meeting	
Sinan B. Sarac	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Tuomo Lapveteläinen	Alternate	Finland	No interests declared	
Pierre Demolis	Member (Vice-Chair)	France	No interests declared	
Harald Enzmann	Member	Germany	No interests declared	
Martina Weise	Alternate	Germany	No restrictions applicable to this meeting	
Dimitrios Kouvelas	Member	Greece	No interests declared	
George Aislaitner	Alternate	Greece	No interests declared	
Agnes Gyurasics	Member	Hungary	No interests declared	
Melinda Sobor	Alternate	Hungary	No interests declared	
Kolbeinn Gudmundsson	Member	Iceland	No interests declared	
David Lyons	Member	Ireland	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			applicable to this meeting	
Patrick Salmon	Alternate	Ireland	No interests declared	
Daniela Melchiorri	Member	Italy	No interests declared	
Juris Pokrotnieks	Member	Latvia	No restrictions applicable to this meeting	
Natalja Karpova	Alternate	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No restrictions applicable to this meeting	
Jacqueline Genoux-Hames	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Helen Vella	Alternate	Malta	No interests declared	
Pieter de Graeff	Member	Netherlands	No interests declared	
Johann Lodewijk Hillege	Alternate	Netherlands	No interests declared	
Karsten Bruins Slot	Member	Norway	No interests declared	
Piotr Fiedor	Member	Poland	No interests declared	
Bruno Sepodes	Member	Portugal	No interests declared	
Nela Vilceanu	Member	Romania	No interests declared	
Jan Mazag	Member	Slovakia	No interests declared	
Ivana Pankuchova	Alternate	Slovakia	No interests declared	
Nevenka Tršinar	Alternate	Slovenia	No interests declared	
Concepcion Prieto Yerro	Member	Spain	No interests declared	
Arantxa Sancho-Lopez	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Greg Markey	Member	United Kingdom	No interests declared	
Rafe Suvarna	Alternate	United Kingdom	No interests declared	
Robert James Hemmings	Co-opted member	United Kingdom	No restrictions applicable to this meeting	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Jean-Louis Robert	Co-opted member	Luxembourg	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Nele Steens	Expert - in person*	Belgium	No interests declared	
Ana Alonso Gutierrez	Expert - in person*	Spain	No interests declared	
Valerie Lescrainier	Expert - in person*	Belguim	No interests declared	
Mair Powell	Expert - in person*	United Kingdom	No interests declared	
Theis Moeslund Jensen	Expert - in person*	Denmark	No restrictions applicable to this meeting	
Eirini Apostolidou	Expert - in	Greece	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
	person*			
Marie-Christine Bielsky	Expert - in person*	United Kingdom	No restrictions applicable to this meeting	
Sabine Mayrhofer	Expert - in person*	Germany	No interests declared	
Jana Schweigertova	Expert - in person*	Slovakia	No restrictions applicable to this meeting	
Patrick Vrijlandt	Expert - in person*	Netherlands	No interests declared	
Emma Cornforth	Expert - in person*	United Kingdom	No interests declared	
Andrea Wallington	Expert - via telephone*	United Kingdom	No interests declared	
Melanie Pires	Expert - in person*	United Kingdom	No interests declared	
Marc Martin	Expert - in person*	France	No interests declared	
Claire-Li Ding	Expert - in person*	France	No interests declared	
Giuseppe Rosano	Expert - in person*	Italy	No interests declared	
Dinah Duarte	Expert - in person*	Portugal	No interests declared	
Marta Herranz Berron	Expert - in person*	Spain	No restrictions applicable to this meeting	
John Johnston	Expert - via telephone*	United Kingdom	No interests declared	
Eva-Gil Berglund	Expert - via telephone*	Sweden	No interests declared	
Sonja Beken	Expert - via telephone*	Belgium	No interests declared	
Olli Tenhunen	Expert - via telephone*	Finland	No restrictions applicable to this meeting	
Karri Penttilä	Expert - via telephone*	Finland	No interests declared	
Marit Hystad	Expert - via telephone*	Norway	No interests declared	
Amany El-Gazayerly	Expert - via telephone*	Netherlands	No interests declared	
Elmer Schabel	Expert - via telephone*	Germany	No interests declared	
Janet Schriever	Expert - via telephone*	Germany	No interests declared	
Nithianandan Nagercoil	Expert - via telephone*	United Kingdom	No restrictions applicable to this meeting	
Cecilia Chisholm	Expert - via telephone*	United Kingdom	No interests declared	
Yolanda Barbachano	Expert - via telephone*	United Kingdom	No interests declared	
Andrea Wallington	Expert - via	United Kingdom	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
	telephone*			
Paula Salmikangas	Expert - via telephone*	Finland	No interests declared	
Nathalie Morgensztejn	Expert - via telephone*	France	No interests declared	
Bertil Jonsson	Expert - via telephone*	Sweden	No interests declared	
Annarita Meneguz	Expert - via telephone*	Italy	No interests declared	
Gedske Thomsen	Expert - via telephone*	Denmark	No interests declared	
Leon van Aerts	Expert - via telephone	Netherlands	No interests declared	
Patients' representative		Patient observer	No interests declared	
Patients' representative		Patient observer	No interests declared	
Patients' representative		Patient mentor	No restrictions applicable to this meeting	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the product(s) they have been invited to talk about.

17. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/